Market Overview:
The global pneumococcal polysaccharide vaccine market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of pneumococcal diseases, rising demand for pneumococcal polysaccharide vaccines due to their safety and efficacy, and growing awareness about preventive measures against pneumococcal diseases. However, the high cost of these vaccines may restrain the growth of this market during the forecast period. Based on type, the global pneumococcal polysaccharide vaccine market is segmented into single dose vial and pre-filled syringe. The single dose vial segment is expected to account for a larger share of the global market in 2018 owing to its lower cost as compared with pre-filled syringes. Based on application, this market is divided into children (2-10 years), adults (10-64 years), and geriatric patients (more than 65 years).
Product Definition:
Pneumococcal polysaccharide vaccine is a vaccine used to prevent pneumococcal disease, which is an infection caused by the Streptococcus pneumoniae bacteria. The vaccine contains purified polysaccharides from the S. pneumoniae bacteria, and it works by stimulating the body's immune system to produce antibodies against these polysaccharides. These antibodies help protect against infection with S. pneumoniae bacteria.
Single Dose Vial:
Single dose vial is a packaging type used for the storage of liquid vaccines. It is mostly used for the storage and delivery of pneumococcal polysaccharide vaccine. The single-dose vials are made up of plastic or glass and are available in different sizes, which can store different volumes of vaccines. They help in delivering each dose accurately at desired intervals with better safety features as compared to other traditional systems such as ampoules or bottles that deliver all doses at once.
Pre-Filled Syringe:
The pre-filled syringe is a device used to inject vaccines. It has gained popularity in the past few years due to its safety and ease of use. The pre-filled syringes are made up of plastic or metal and are available in different sizes ranging from 0.5 ml to 10 ml with various needle types including straight, bent, and curved needles.
Application Insights:
Based on the application, the global pneumococcal polysaccharide vaccine market is segmented into children (2-10 age), adult (10-64 age) and geriatric population above 65 years. The geriatric population segment held a major share of over 40% in 2017 owing to increasing prevalence of chronic diseases such as diabetes and pneumonia. Moreover, this segment is anticipated to witness lucrative growth during the forecast period due to rising number of older people worldwide.
The global PCP vaccine market witnessed significant growth in recent years owing to its usage for prevention against bacterial pneumonia among young children as well as adults. This preventive measure has led to reduced hospital admissions and deaths caused by Pneumonia among both these groups globally which supports further development of this product line for wider applications across all ages globally.
Regional Analysis:
North America dominated the global market in 2017. The rising prevalence of pneumococcal disease, increasing number of government initiatives to raise awareness about the vaccine, and high investment by key players in this region are some factors contributing to its largest share. In addition, a favorable reimbursement scenario is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to an increase in immunization activities against pneumococcal diseases coupled with growing healthcare expenditure levels and improved access for people living in remote areas. Moreover, increasing foreign direct investments coupled with supportive policies implemented by governments towards improving public health infrastructure will further fuel regional demand during the forecast period.
Growth Factors:
- Increasing incidence of pneumococcal infections: The global incidence of pneumococcal infections is increasing due to the spread of the disease in developing countries and the emergence of antibiotic-resistant strains. This is expected to drive demand for pneumococcal polysaccharide vaccines.
- Growing awareness about pneumococcal diseases: There is growing awareness among people about the risks and symptoms associated with pneumococcal diseases, which is expected to boost demand for pneumococcal polysaccharide vaccines.
- Rising number of elderly population: The number of elderly people is increasing globally, which will lead to an increase in cases of pneumonia caused by Streptococcus pneumoniae bacteria – a major target for vaccination with PPV23 vaccine. This will fuel growth in the PPV23 vaccine market over the forecast period.
- Technological advancements in vaccine production: There has been significant progress made in technology used for manufacturing vaccines, which has led to an increase in production capacity and reduction in costs – driving down prices and making these products more affordable globally. This trend is anticipated to continue over the next few years, propelling growth prospects for the PPV23 vaccine market . 5) Expanding distribution networks: Pharmaceutical companies are expanding their distribution networks across regions, thereby enabling wider access to these products
Scope Of The Report
Report Attributes
Report Details
Report Title
Pneumococcal Polysaccharide Vaccine Market Research Report
By Type
Single Dose Vial, Pre-Filled Syringe
By Application
Children (2-10 Age), Adult (10-64 Age), Geriatric (More Than 65 Age)
By Companies
Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Sanofi Pasteur, China National Biotec Group, Astellas Pharma Inc, Serum Institute of India Pvt. Ltd, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Pneumococcal Polysaccharide Vaccine Market Report Segments:
The global Pneumococcal Polysaccharide Vaccine market is segmented on the basis of:
Types
Single Dose Vial, Pre-Filled Syringe
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Children (2-10 Age), Adult (10-64 Age), Geriatric (More Than 65 Age)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co., Inc.
- Pfizer Inc.
- Glaxosmithkline Plc.
- Sanofi Pasteur
- China National Biotec Group
- Astellas Pharma Inc
- Serum Institute of India Pvt. Ltd
- ...
Highlights of The Pneumococcal Polysaccharide Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Single Dose Vial
- Pre-Filled Syringe
- By Application:
- Children (2-10 Age)
- Adult (10-64 Age)
- Geriatric (More Than 65 Age)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pneumococcal Polysaccharide Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pneumococcal polysaccharide vaccine (PPV) is a vaccine used to prevent pneumococcal infections. PPV is made from the capsular polysaccharides of Streptococcus pneumoniae, and it helps protect against pneumococcal infections in people aged 2 years or older. PPV is given as a shot in the arm. It can help prevent serious pneumococcal infections, including meningitis, pneumonia, and death.
Some of the key players operating in the pneumococcal polysaccharide vaccine market are Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Sanofi Pasteur, China National Biotec Group, Astellas Pharma Inc, Serum Institute of India Pvt. Ltd.
The pneumococcal polysaccharide vaccine market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pneumococcal Polysaccharide Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pneumococcal Polysaccharide Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pneumococcal Polysaccharide Vaccine Market - Supply Chain
4.5. Global Pneumococcal Polysaccharide Vaccine Market Forecast
4.5.1. Pneumococcal Polysaccharide Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pneumococcal Polysaccharide Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pneumococcal Polysaccharide Vaccine Market Absolute $ Opportunity
5. Global Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
5.3.1. Single Dose Vial
5.3.2. Pre-Filled Syringe
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
6.3.1. Children (2-10 Age)
6.3.2. Adult (10-64 Age)
6.3.3. Geriatric (More Than 65 Age)
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pneumococcal Polysaccharide Vaccine Demand Share Forecast, 2019-2029
9. North America Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
9.4.1. Children (2-10 Age)
9.4.2. Adult (10-64 Age)
9.4.3. Geriatric (More Than 65 Age)
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
9.7.1. Single Dose Vial
9.7.2. Pre-Filled Syringe
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pneumococcal Polysaccharide Vaccine Demand Share Forecast, 2019-2029
10. Latin America Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
10.4.1. Children (2-10 Age)
10.4.2. Adult (10-64 Age)
10.4.3. Geriatric (More Than 65 Age)
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
10.7.1. Single Dose Vial
10.7.2. Pre-Filled Syringe
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pneumococcal Polysaccharide Vaccine Demand Share Forecast, 2019-2029
11. Europe Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
11.4.1. Children (2-10 Age)
11.4.2. Adult (10-64 Age)
11.4.3. Geriatric (More Than 65 Age)
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
11.7.1. Single Dose Vial
11.7.2. Pre-Filled Syringe
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pneumococcal Polysaccharide Vaccine Demand Share, 2019-2029
12. Asia Pacific Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
12.4.1. Children (2-10 Age)
12.4.2. Adult (10-64 Age)
12.4.3. Geriatric (More Than 65 Age)
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
12.7.1. Single Dose Vial
12.7.2. Pre-Filled Syringe
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pneumococcal Polysaccharide Vaccine Demand Share, 2019-2029
13. Middle East & Africa Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
13.4.1. Children (2-10 Age)
13.4.2. Adult (10-64 Age)
13.4.3. Geriatric (More Than 65 Age)
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
13.7.1. Single Dose Vial
13.7.2. Pre-Filled Syringe
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pneumococcal Polysaccharide Vaccine Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Pneumococcal Polysaccharide Vaccine Market: Market Share Analysis
14.2. Pneumococcal Polysaccharide Vaccine Distributors and Customers
14.3. Pneumococcal Polysaccharide Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck & Co., Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Glaxosmithkline Plc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sanofi Pasteur
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. China National Biotec Group
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Astellas Pharma Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Serum Institute of India Pvt. Ltd
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. ...
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
